Stay updated with breaking news from Mo Khan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HVIVO plc, the world leader in infectious disease testing, has reported double-digit revenue growth and improved EBITDA margins and cash for 2023. The company expects to pay an annual dividend and has set a new revenue target of £100 million by 2028. The growing orderbook and high revenue visibility indicate a strong market position.
Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client.
HVIVO plc £6.3m HRV Contract Signed with Biotechnology Client
American investors have good reason to feel festive. US markets have soared during 2023, fed by better-than-expected economic figures and a rebound in titans such as Amazon, Apple and Meta.
Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in price over the year.